Amide Tech

Amide Tech is a private, early-revenue biotech company founded in 2015 as an MIT spinout. It operates as a Contract Development and Manufacturing Organization (CDMO) for complex peptides, leveraging its proprietary AFPS technology to enable the synthesis of peptides up to 120 amino acids reliably and with a turnaround time as fast as 4 days. The company addresses a critical bottleneck in peptide sourcing for drug discovery, particularly for novel therapeutic modalities like macrocyclic peptides, D-peptides, and branched structures. In 2023, Amide announced its manufacturing platform and raised $16.5 million in funding to scale its operations.

Automated Fast Flow Peptide Synthesis (AFPS) - A flow chemistry-based platform for rapid, reliable synthesis of long and complex peptides, including those with unnatural amino acids, branched structures, and mirror-image configurations.

Amide competes with traditional peptide CMOs using solid-phase synthesis and companies using biological expression systems. Its differentiation is speed (4-day turnaround) and ability to synthesize complex, unnatural structures (up to 120 aa) that others refuse or fail to produce.